A director converts awards into 4,224 shares at Quanterix (QTRX), bringing her holdings to 15,883 shares.
Quanterix director Ivana Magovcevic-Liebisch converted 4,224 restricted stock units (RSUs) into common shares on October 2, 2026. This transaction increased her direct common share holdings to 15,883, while she now holds 4,352 restricted stock units. The RSUs were part of a 12,800-unit grant from October 2, 2024, with a vesting schedule over three years.
For Q3 board service, Quanterix (QTRX) grants director Donnelly 6,964 shares instead of cash.
Quanterix Corp director William P. Donnelly received 6,964 shares of common stock on October 1, 2026, priced at $3.41 per share, in lieu of cash fees for his third-quarter 2026 board and committee service. This transaction increased his direct holdings to 169,365 shares. The filing, categorized as a Form 4, indicates a neutral impact and sentiment according to Rhea-AI.
A 4,398-share grant replaces Q3 cash fees for Quanterix (QTRX) director Scott Mendel.
Quanterix Corp. director Scott Mendel received a grant of 4,398 common shares on October 1, 2026, in lieu of cash fees for his board and committee service during the third quarter of 2026. This transaction increased his direct common-stock position to 28,454 shares, with the reported per-share amount being $3.41. The filing, categorized as neutral in impact and sentiment, details the stock grant as a compensation method for his services.
Spatial proteomics panels advance with Quanterix at ESSB 2026
Quanterix Corporation is launching three new spatial proteomics programs at the European Society for Spatial Biology (ESSB) meeting, moving them from preview to commercial availability. These include the global release of the PhenoCode Molecular Barcoding Kit, the Q4 2026 shipment of two new PhenoCycler-Fusion content panels for Tumor Immune Microenvironment (TIME) and high-plex ADC analysis, and the opening of its Accelerator Laboratory for custom antibody-drug conjugate (ADC) panel development requests under clinical quality frameworks. These advancements aim to address key challenges in high-plex spatial proteomics, such as customizing panels and integrating ADC target expression with immune contexture for translational and clinical research.
Quanterix Advances Spatial Biology Content Innovation
Quanterix announced significant advancements in its Content Innovation Engine for spatial biology, with new updates revealed at the European Society for Spatial Biology (ESSB) meeting. The company has released its PhenoCode™ 2.0 Molecular Barcoding Kit and plans to ship the TIME panel and a high-plex ADC panel in Q4 2026. Additionally, Quanterix's Accelerator Laboratory Services are now offering custom ADC panel development for biopharma and translational teams.
Quanterix Corporation (QTRX) Stock Price, News, Quote & History
This article provides a detailed overview of Quanterix Corporation (QTRX), a life sciences company specializing in medical devices and diagnostics. It includes current stock performance, key financial metrics, company overview, recent news, performance against benchmarks, earnings trends, analyst insights, and valuation statistics. The company's stock is currently trading at $3.44, up 5.20%, with a market capitalization of $162.688 million.
365,326 stock units go to two new employees at Quanterix. They vest over four years.
Quanterix (NASDAQ: QTRX) announced inducement grants of restricted stock units (RSUs) to its new Chief Commercial Officer, James Gute, and two other employees. Mr. Gute received 260,315 RSUs, and the other two employees collectively received 365,326 RSUs. These RSUs will vest in four equal annual installments and were granted under the company's 2025 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Quanterix Corp (NASDAQ: QTRX) Grants 260,315 Derivative Securities to Chief Commercial Officer Gute James Edward Jr.
Quanterix Corp (NASDAQ: QTRX) awarded 260,315 derivative securities to its Chief Commercial Officer, Gute James Edward Jr., on September 15, 2026. This transaction increased his total derivative holdings to 260,315 securities, representing 100% of his updated derivative securities position in the company. The award is classified under code A, indicating an award or grant, and constitutes the entirety of his derivative securities holding in Quanterix.
Quanterix (QTRX) awards its CCO 260K RSUs
Quanterix (QTRX) has awarded its Chief Commercial Officer, James Edward Gute Jr., 260,315 restricted stock units (RSUs). These RSUs will vest in four equal annual installments over four years, contingent on his continued employment. This grant aligns the executive's compensation with long-term service and company performance.
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation announced inducement grants to its newly appointed Chief Commercial Officer, James Gute, and two other employees. Mr. Gute received 260,315 restricted stock units (RSUs), while the other two employees collectively received 365,326 RSUs. These grants, approved by the Compensation Committee, vest over four years and are intended to be an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Quanterix Names Yuri Fesko Chief Medical Officer as Diagnostics Business Expands
Quanterix Corporation has appointed Dr. Yuri Fesko as its chief medical officer to spearhead the expansion of its diagnostics business. Fesko will provide medical and clinical leadership, focusing on the broader market launch of the Lucent AD® Complete Alzheimer’s disease test and advancing regulatory work for the HD-X instrument. His extensive background in clinical affairs and precision medicine, particularly from his previous role at Quest Diagnostics, is expected to be instrumental in commercializing Quanterix's biomarker technologies into clinical applications and regulated diagnostic products.
Quanterix CTO Michael Francis Executes 1,558 Stock Options and Forfeits 467 Shares on September 15, 2026
Quanterix CTO Michael Francis exercised options for 1,558 shares and forfeited 467 shares on September 15, 2026. These transactions updated his total holdings to 38,701 shares before forfeiture and 38,452 shares after, with 24,189 derivative securities remaining. The forfeited shares were valued at $2.72 per share, and the forfeitures were marked with transaction code F, indicating shares withheld for taxes or exercise prices.
Quanterix appoints Yuri Fesko as chief medical officer By Investing.com
Quanterix Corporation has announced the appointment of Dr. Yuri Fesko as Chief Medical Officer. In this role, Fesko will provide medical and clinical leadership across various departments, especially as the company prepares to launch its Lucent AD Complete five biomarker test for Alzheimer’s Disease. Fesko previously served as Chief Medical Officer at Quest Diagnostics and brings extensive experience in precision medicine strategies.
Quanterix appoints Yuri Fesko as chief medical officer
Quanterix Corporation (NASDAQ:QTRX) has appointed Dr. Yuri Fesko as its new Chief Medical Officer. Dr. Fesko will lead medical and clinical initiatives across various departments as the company prepares to launch its Lucent AD Complete five biomarker test for Alzheimer's Disease. He brings extensive experience in precision medicine and advanced diagnostics from his previous role as CMO at Quest Diagnostics.
Quanterix Corp (QTRX) Earnings, Actual EPS, EPS Estimates & Results
This article provides an overview of Quanterix Corp's (QTRX) earnings, including upcoming estimates and historical performance. It details estimated EPS and revenue for Q3 '26, as well as actual reported EPS, estimates, and surprise percentages for previous quarters. The data indicates a mix of missed and beaten EPS estimates in recent fiscal periods.
Bruker Corporation Executive is Named Finance Chief at Quanterix
Quanterix Corporation has appointed Jason Faessler, formerly of Bruker Corporation, as its new chief financial officer. Faessler's extensive experience in finance leadership within the life science tools industry is expected to be crucial for Quanterix's future growth. He previously held senior financial roles at PAREXEL, EMC (now Dell), and Harvard Business Publishing.
Quanterix (QTRX) director adds 3,955 shares via RSU vest
Quanterix Corp (QTRX) director Jeffrey Thomas Elliott converted 3,955 restricted stock units (RSUs) into common stock on August 19, 2026, increasing his direct common stock holdings to 15,345 shares. He still holds 4,075 RSUs from an original grant of 11,985 RSUs issued on August 19, 2024, which vest over three years. This transaction was an exercise/conversion of a derivative security and not an open-market purchase or sale.
Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team
Quanterix Corporation has appointed Geoff Albrecht, formerly of Quest Diagnostics, as Senior Vice President and General Manager of Diagnostics. Albrecht will lead Quanterix’s Diagnostics strategy, focusing initially on Alzheimer's Disease Diagnostics, and will be responsible for scaling the company's diagnostics portfolio into a significant revenue driver. This hire emphasizes Quanterix's commitment to making diagnostics a core part of its future growth, leveraging Albrecht's 25 years of commercial leadership experience.
Quanterix (QTRX) director now holds 162,401 shares
Quanterix Corp (QTRX) director William P. Donnelly reported the vesting and conversion of 2,802 restricted stock units (RSUs) into common stock on August 17, 2026. Following this transaction, Donnelly directly holds 162,401 shares of Quanterix common stock. The RSUs were originally granted on August 17, 2023, with a three-year vesting schedule.
Quanterix (QTRX) CCO files initial ownership report with no shares
James Edward Gute Jr., Chief Commercial Officer of Quanterix Corp (QTRX), has filed an initial statement of beneficial ownership of securities (Form 3) with no current reportable holdings or transactions in Quanterix Corp securities. This filing indicates that as of the report date, he does not beneficially own any shares of the company, serving as an initial inventory sheet for his insider status. The document also details the specifics of the Form 3 filing, including the date of event and reporting person's information.
Quanterix files Form 3 for Chief Commercial Officer James Edward Gute Jr
Quanterix has filed a Form 3 for James Edward Gute Jr., officially naming him as Chief Commercial Officer. The filing was dated August 17, 2026. This news brief was generated by AI based on information from the SEC's EDGAR system.
Quanterix (QTRX) CTO converts RSUs, withholds shares for taxes
Quanterix Corp's CTO, Michael Francis Miller, recently converted 1,558 restricted stock units (RSUs) into common stock and had 467 shares withheld for tax liabilities at $2.59 per share. This transaction, filed on August 15, 2026, is largely administrative, reflecting equity compensation rather than market activity. Miller's holdings now include 36,791 RSUs and 37,250 common stock shares directly.
Quanterix (NASDAQ:QTRX) Price Target Cut to $3.00 by Analysts at Canaccord Genuity Group
Canaccord Genuity Group has reduced its price target for Quanterix (NASDAQ:QTRX) from $4.00 to $3.00, while maintaining a "hold" rating, suggesting a potential upside of 15.8% from its current price. This cut follows Quanterix missing analyst expectations in its latest quarterly earnings, reporting a loss of $1.04 per share against an anticipated $0.41 loss and revenues of $32.91 million versus a $37.48 million consensus. The company currently holds an average "Reduce" rating from analysts with a consensus price target of $3.00.
Canaccord cuts Quanterix stock price target on weak Q2 results
Canaccord has lowered its price target for Quanterix Corp. (NASDAQ:QTRX) to $3.00 from $4.00, while maintaining a Hold rating, due to weaker-than-expected Q2 2026 results and ongoing commercial execution challenges. The company's stock has seen a significant decline, burning through cash, despite progress in Alzheimer’s diagnostics and an InvestingPro analysis suggesting undervaluation. Quanterix reported Q2 revenue of $32.9 million, below consensus estimates, and announced organizational changes to address its performance issues.
Canaccord cuts Quanterix stock price target on weak Q2 results By Investing.com
Canaccord has reduced its price target for Quanterix Corp. (NASDAQ:QTRX) from $4.00 to $3.00, maintaining a Hold rating, following the company's weaker-than-expected second-quarter 2026 results. The stock has seen a significant decline, reflecting investor concerns over commercial execution challenges and cash burn, despite some progress in Alzheimer's diagnostics. Quanterix reported Q2 revenue of $32.9 million, missing consensus estimates, and announced organizational changes to address these issues.
Quanterix (QTRX) Q2 2026 Earnings Call Transcript
Quanterix reported Q2 2026 earnings, revealing a revenue of $32.9 million, a 34% increase year-over-year but a 23% pro forma decline. The company lowered its full-year 2026 revenue guidance to $142 million-$148 million due to commercial execution challenges and market softness, pushing back its cash flow break-even target to 2027. Despite these challenges, Quanterix is reorganizing its commercial team, making strategic investments in its Alzheimer’s disease diagnostics business, and announced new leadership appointments to drive improved performance in the second half of 2026 and beyond.
Executive Chair of Quanterix Picks Up 62% More Stock
Quanterix Corporation's Executive Chair, William P. Donnelly, recently purchased US$286k worth of the company's stock at US$2.88 per share, increasing his holding by 62%. This transaction represents the largest insider purchase in the last year, suggesting confidence in the company's future despite it not having made a profit in the last twelve months. Insiders own 6.8% of the company, and while not considered high, the transaction history indicates optimism.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix (NASDAQ: QTRX) is restructuring its sales organization into specialized teams for spatial biology, Simoa products, and clinical-trial services to improve commercial execution. The company is targeting a Q4 FDA decision for its LucentAD Complete Alzheimer's blood test, with a goal of achieving $10 million in diagnostics revenue in 2026. Despite continued pressures in academic and biopharma markets, Quanterix aims to stabilize its research tools business and has pushed its cash-flow breakeven target to next year.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix is reorganizing its sales teams into specialized units for spatial biology, Simoa products, and clinical-trial services to improve commercial execution. The company is also aiming for an FDA decision on its LucentAD Complete Alzheimer’s blood test by Q4, with a goal of achieving $10 million in diagnostics revenue in 2026. Despite academic and biopharma funding pressures, Quanterix anticipates flat revenue in Q3 before sequential improvement in Q4, though its cash-flow breakeven target has been pushed to next year.
Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Quanterix (NASDAQ:QTRX) from a "Hold" to a "Sell" rating, while other analysts maintain "Hold" ratings, leading to an overall "Reduce" consensus and an average price target of $3.50. The company's shares opened significantly lower at $2.59, trading below key moving averages, and recently missed analyst expectations for both earnings and revenue in its latest quarterly report. Institutional investors have also adjusted their positions in the life sciences and diagnostics company.
Quanterix Corp (QTRX) director-linked trusts buy 99,400 shares in open market
Quanterix Corp (QTRX) director William P. Donnelly, through trusts, indirectly purchased a total of 99,400 common shares in open-market transactions on August 12 and 13, 2026. The purchases were made at weighted average prices of $2.75 and $2.93 per share, respectively, totaling approximately $286,000. These transactions were disclosed in a Form 4 filing, indicating a positive sentiment and moderate filing impact.
Quanterix Insider Bought Shares Worth $286,354, According to a Recent SEC Filing
An insider at Quanterix Corporation (QTRX) recently purchased shares valued at $286,354, according to a new SEC filing. This transaction was published on August 14, 2026, at 04:11 pm EDT. The article also provides recent news on Quanterix, including their Q2 2026 earnings results and revised financial guidance.
Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts
Quanterix Corporation recently reported disappointing second-quarter results, with revenues falling 12% short of analyst estimates and statutory losses significantly exceeding expectations. Following this, analysts have made serious cuts to their revenue outlook for 2026, now expecting a 6.8% decline, and anticipate increased losses per share. The average price target has also fallen by 23%, indicating greater pessimism about the company's intrinsic value and future performance compared to the wider industry.
Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher
Quanterix (QTRX) recently released its Q2 2026 earnings report, showing higher revenue but a wider net loss and a lowered full-year revenue outlook, alongside the appointment of a new Chief Commercial Officer. Despite these mixed results, the stock saw a brief rebound, suggesting investors are re-evaluating its potential. Simply Wall St's analysis indicates Quanterix is currently undervalued, with a fair value of $4.33 against a closing price of $2.63, driven by an expanded addressable market through the combined Quanterix Akoya entity.
TD Cowen Issues Pessimistic Forecast for Quanterix (NASDAQ:QTRX) Stock Price
TD Cowen has lowered its price target for Quanterix (NASDAQ:QTRX) from $4.00 to $3.00, maintaining a "hold" rating due to the company's recent earnings and revenue misses. The stock, currently trading near its 52-week low at $2.48, holds an average analyst rating of "Reduce" with a consensus target price of $3.50. Quanterix reported a quarterly loss of $1.04 per share against an estimated loss of $0.41, and revenue of $32.91 million fell short of the $37.46 million forecast.
Quanterix 2Q Rev $32.9M >QTRX
This article provides a brief update on Quanterix's Q2 revenue. The company reported revenue of $32.9 million, surpassing analyst expectations. This financial update indicates a positive performance for Quanterix during the second quarter.
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even
Quanterix has lowered its 2026 revenue forecast and pushed its cash-flow break-even target to 2027 due to weaker-than-expected commercial performance and execution challenges. The company reported 34% revenue growth in Q2 2026 but reduced its full-year outlook by $21-$27 million and expects year-end cash to be $80 million, down from $100 million previously. In response, Quanterix is reorganizing commercial operations and strengthening leadership while continuing its focus on Alzheimer's diagnostics.
Earnings call transcript: Quanterix Q2 2026 revenue miss sends shares down 43%
Quanterix reported Q2 2026 revenue of $32.9 million, significantly missing analyst expectations of $38.06 million and causing shares to drop 43%. The company revised its full-year 2026 revenue guidance downwards and pushed back its cash flow breakeven target to 2027, citing commercial execution issues and softness in academic and government spending. Despite challenges, Quanterix is reorganizing its sales force, investing in its diagnostics business, particularly the LucentAD Complete Alzheimer's test, and announced new leadership appointments to drive future growth.
Quanterix Corp (QTRX) Misses Q2 Earnings Estimates with EPS at -$1.04 and Revenue of $32.9M; Is the Stock 65.9% Undervalued? GF Score: 63/100
Quanterix Corp (QTRX) reported its Q2 2026 financial results, missing analyst estimates with a revenue of $32.9 million against an expected $37.46 million, and an adjusted loss per share of $1.04 compared to a forecasted $0.40 loss. Despite challenges like market softness and execution issues, the company saw a 34% revenue increase year-over-year and improved its adjusted EBITDA loss and cash preservation. GuruFocus data indicates QTRX is significantly undervalued by 65.9%, with a GF Score of 63/100, suggesting a potential buying opportunity for value investors.
Quanterix Names Jim Gute Chief Commercial Officer to Accelerate Growth
Quanterix Corporation has appointed Jim Gute as Chief Commercial Officer to lead its commercial operations. Gute will focus on expanding the company's customer base, increasing the utilization of its installed systems, and strengthening commercial execution as Quanterix prepares to grow its diagnostics business and core research offerings. His experience from Exact Sciences and GE Healthcare will be instrumental in commercializing Quanterix's ultra-sensitive protein detection (Simoa) and spatial analysis technologies, particularly as the company moves into diagnostic applications and integrates its recent acquisition of Akoya Biosciences.
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary
Quanterix Corp (QTRX) reported its financial results for the quarter ended 2026, with revenues reaching $32.91 million and a net loss of $48.93 million, resulting in a diluted loss per share of $1.04. This represents a significant increase in revenue and net loss compared to the prior year quarter, largely driven by the acquisition of Akoya. The company also highlighted regulatory progress with an Alzheimer's blood test and operational achievements in integrating Akoya.
Quanterix (QTRX) boosts revenue as Alzheimer’s bets rise amid big write-downs
Quanterix reported a 34% increase in Q2 2026 revenue to $32.9 million, largely driven by the acquisition of Akoya Biosciences, but also recorded significant net losses of $48.9 million due to substantial goodwill and R&D impairments. The company is strategically shifting its focus towards Alzheimer's diagnostics, submitting a 510(k) for a multi-analyte blood test and securing Medicare and commercial coverage for its LucentAD Complete LDT, while also implementing cost synergies from the Akoya acquisition. Despite revenue growth, Quanterix anticipates continued operating losses into 2027 and plans further investments in commercial and diagnostic capabilities.
Quanterix Q2 2026 earnings: Revenue rises 34% as outlook is cut
Quanterix (QTRX) reported a 34% rise in Q2 2026 revenue to $32.9 million, primarily driven by product sales. Despite a narrower adjusted EBITDA loss, the GAAP net loss widened significantly to $48.9 million due to a $26.9 million Akoya-related goodwill impairment. The company cut its full-year guidance, citing execution challenges and market softness, and pushed its cash-flow breakeven target to 2027.
Quanterix Corp (QTRX) Stock News Today
This article provides an update on Quanterix Corp (QTRX) stock, noting a recent price increase of 5.22% to $4.030. It indicates that more news regarding earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for financial information on QTRX.
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Quanterix Corp (QTRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 3 analysts, the stock has a "Hold" rating with an average price target of $6.50, suggesting a potential upside of 16.80%. The article also includes expected revenue and EPS for upcoming quarters.
Earnings To Watch: Quanterix Corp (QTRX) Q2 2026 -- GF Value Sees 253% Upside
Quanterix Corp (QTRX) is set to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $37.46 million and an expected loss of $0.40 per share. While full-year 2026 revenue estimates have slightly declined, earnings estimates for 2027 have also seen a decrease. Analysts have an average "Hold" recommendation for QTRX with a 12-month target price of $4.33, while GuruFocus estimates a significant upside of 253.46% based on its GF Value of $13.52.
First Eagle Investment Management (QTRX) discloses 5.8% Quanterix ownership via advised funds
First Eagle Investment Management, LLC has reported a beneficial ownership of 2,753,165 shares, or 5.8% of Quanterix Corp (QTRX) common stock, as of June 30, 2026. These shares grant First Eagle sole voting and dispositive power. The First Eagle Small Cap Opportunity Fund, advised by First Eagle, accounts for 2,421,533 of these shares, representing 5.1% of Quanterix's common stock.
Quanterix CEO to give company update in Aug. 12 webcast
Quanterix Corporation (NASDAQ: QTRX) announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will provide a company update during a live webcast fireside chat on August 12, and CTO Michael Miller will join a panel discussion on Neurology Diagnostics. The company will also hold one-on-one investor meetings at the event.
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Quanterix Corporation announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will present in a fireside chat, and Chief Technology and Product Officer Michael Miller will join a panel on Neurology Diagnostics. The management team, including CFO Jason Faessler, will also hold one-on-one investor meetings during the event.
Quanterix Corp (NASDAQ: QTRX) CTO reports 130 RSUs vesting, 39 shares withheld
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, reported the conversion of 130 restricted stock units (RSUs) into common shares and the disposal of 39 shares at $3.48 each to cover tax liabilities on July 31, 2026. This transaction is part of a larger RSU grant from September 2022, with a specific vesting schedule. The filing indicates a neutral impact and sentiment, and these transactions were not affirmed under a Rule 10b5-1 trading plan.
